The Clinical Use Of Levonorgestrel Releasing Intrauterine Systems (LNG-IUS)

Levonorgestrel releasing-intrauterine systems (LNG-IUS) were originally developed as a method of contraception in the mid 1970s. It is a highly effective contraceptive method with few contraindications and few side effects. All studies have reported high contraceptive efficacy and reversible long-term method of contraception. This an improvement in menstrual blood loss in women with idiopathic menorrhagia, menorrhagia due to fibroids, and excellent endometrial protection during postmenopausal estrogen therapy. There is limited evidence to suggest that LNG-IUS may also be beneficial in women with endometriosis, adenomyosis, fibroids, endometrial hyperplasia and early stage endometrial cancer (where the patient is deemed unfit for primary surgical therapy).The most frequent side effects are unscheduled erratic menstrual bleeding, irregular uterine bleeding , which usually occur during the first stage of LNG-IUS insertion .This article provides a perspective on the use of the levonorgestrel-releasing intrauterine system as a contraceptive method and as therapy in different situations, as well as presenting the corresponding controversies and unresolved issues. To evaluate patient satisfaction and improvement in quality of life (QoL) among women .This systematic enquiry and overview evaluates the quality of evidence relating to the contraceptive and non-contraceptive therapeutic uses of LNG-IUS in gynaecology.